Last $42.46 USD
Change Today +0.03 / 0.07%
Volume 4.7M
ABT On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
London
Sao Paulo
Frankfurt
As of 8:04 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT) Snapshot

Open
$42.34
Previous Close
$42.43
Day High
$42.67
Day Low
$42.12
52 Week High
09/19/14 - $44.20
52 Week Low
01/29/14 - $35.65
Market Cap
63.8B
Average Volume 10 Days
6.3M
EPS TTM
$1.54
Shares Outstanding
1.5B
EX-Date
10/10/14
P/E TM
27.6x
Dividend
$0.88
Dividend Yield
2.07%
Current Stock Chart for ABBOTT LABORATORIES (ABT)

abbott laboratories (ABT) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as various forms of prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, such as cataract surgery, LASIK surgery, and contact lens care and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra Co-operative Group Ltd. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

69,000 Employees
Last Reported Date: 02/21/14
Founded in 1888

abbott laboratories (ABT) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $969.7K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $614.6K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $629.5K
Compensation as of Fiscal Year 2013.

abbott laboratories (ABT) Key Developments

Abbott Laboratories Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014 ; Revises Earnings Guidance for the Full Year 2014 ; Provides Earnings Guidance for the Fourth Quarter of 2014

Abbott Laboratories announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $5,104 million, operating earnings of $731 million, earnings from continuing operations before taxes of $718 million, earnings from continuing operations of $440 million or $0.29 per diluted share, net earnings of $538 million or $0.36 per diluted share compared to the net sales of $4,825 million, operating earnings of $473 million, earnings from continuing operations before taxes of $481 million, earnings from continuing operations of $644 million or $0.41 per diluted share, net earnings of $966 million or $0.61 per diluted share for the same quarter a year ago. For the year to date, the company reported net sales of $14,957 million, operating earnings of $1,772 million, earnings from continuing operations before taxes of $1,716 million, earnings from continuing operations of $1,089 million 0 of $0.71 per diluted share, net earnings of $1,380 million 0 of $0.9 per diluted share compared to the net sales of $14,643 million, operating earnings of $1,505 million, earnings from continuing operations before taxes of $1,433 million, earnings from continuing operations of $1,504 million 0 of $0.95 per diluted share, net earnings of $1,987 million 0 of $1.25 per diluted share for the same period a year ago. The company is raising the mid-point and narrowing its full-year 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27 from $2.19 to $2.29, representing double-digit growth. This guidance includes results from the developed markets branded generics pharmaceuticals business, reported as discontinued operations due to the pending sale of this business to Mylan. Projected full-year 2014 EPS under GAAP is $1.22 to $1.24. The company fourth-quarter 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70, representing double-digit growth. Abbott forecasts specified items for the fourth quarter 2014 of $0.36. Including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34 for the fourth quarter. This guidance includes results from both continuing and discontinued operations.

The U.S. District Court for the Northern District of Illinois Dismisses Racketeer Influenced and Corrupt Organizations Act Claims Brought by a Health Benefits Plan Provider Against Abbott Laboratories and AbbVie Inc

The U.S. District Court for the Northern District of Illinois dismissed Racketeer Influenced and Corrupt Organizations Act (RICO) claims brought by a health benefits plan provider against two pharmaceutical companies arising from the defendants' issuance of co-pay subsidies to certain patients. New England Carpenters Health and Welfare Fund sued Abbott Laboratories and AbbVie Inc. a treatment for rheumatoid arthritis, and AndroGel, a replacement therapy for men with low testosterone levels. The plaintiffs sought to recover damages resulting from the defendants' co-pay subsidy programs. The complaint alleged that the defendants' co-pay subsidies, in the form of savings cards that discounted the patients' co-pay obligations for those medications, frustrated pharmacies' contractual obligation to collect co-pays directly from the fund's insureds, and further alleged that the defendants instructed pharmacies to conceal the use of their co-pay subsidies from the fund by instructing pharmacies to process the subsidies as if they were a form of secondary insurance. The fund alleged violations of the RICO Act and tortious interference with contract. The defendants moved to dismiss. The district court held the complaint failed to allege facts sufficient to raise a plausible inference that pharmacies were fraudulently processing savings cards as secondary insurance on behalf of an 'enterprise,' as that term was defined by RICO. The alleged ties between the pharmacies and the defendants were not sufficient to support a finding of concerted illegal conduct and there were no allegations that the pharmacies involved themselves in the defendants' marketing strategy or in the administration of the defendants' co-pay subsidies. As a result, the complaint failed to allege a substantive RICO claim, and accordingly, the district court granted the defendants' related motion to dismiss. With the RICO claims no longer pending, the district court declined to exercise supplemental jurisdiction over the fund's remaining state law claims and dismissed the action.

Abbott Laboratories to Report Q3, 2014 Results on Oct 22, 2014

Abbott Laboratories announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Oct 22, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $42.46 USD +0.03

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $240.33 USD +3.12
Danaher Corp $77.96 USD +0.60
Eli Lilly & Co $66.05 USD +1.70
Medtronic Inc $66.56 USD +0.95
Teva Pharmaceutical Industries Ltd $53.62 USD +0.02
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 33.5x
Price/Sales 2.9x
Price/Book -- Not Meaningful
Price/Cash Flow 23.5x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.